Literature DB >> 15744468

Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance.

Andreas Schuchert1, Giuseppe Boriani, Christian Wollmann, Mauro Biffi, Martin Kühl, Johannes Sperzel, Sascha Stiller, Gianni Gasparini, Dirk Böcker.   

Abstract

INTRODUCTION: Atrial tachyarrhythmias are a common co-morbidity in patients with an ICD indication. Recently introduced ICD's are equipped to independently detect and treat atrial and ventricular tachyarrhythmias. The purpose of this prospective study was to evaluate the incidence and termination of spontaneous atrial and ventricular tachyarrythmias in patients with a history of atrial tachyarrhythmias. METHODS AND
RESULTS: Ninety patients, 70% male with an ICD indication and history of atrial tachyarrhythmia (LVEF 45 +/- 6%, [AT/AF indication 55 +/- 10, AT/VT 45 +/- 16], 46% CAD) were enrolled and 89 were implanted with a VENTAK PRIZM AVT (Guidant). Spontaneous atrial and ventricular tachyarrhythmias were printed and evaluated during an average follow-up period of 272 +/- 72 days utilizing the stored intracardial electrogram function of the device. Nineteen patients (21%) presented had only atrial tachyarrhythmias, 32 patients (36%) had both atrial and ventricular tachyarrhythmias and 18 patients (20%) had only ventricular tachyarrhythmias. Patients with only atrial tachyarrhythmias had a total of 3274 atrial episodes; 2002 terminated spontaneously, 1264 were treated with ATP and 8 with shock therapy. ATP was successful in 735 (58%) of 1264 episodes. Patients with both atrial and ventricular tachyarrhythmias had 7277 documented atrial tachyarrhythmias, 5231 terminated spontaneously, 1153 of 2009 were terminated by ATP (57.4%) and 37 by shock therapy (20 patient controlled). Atrial tachyarrhythmias identified as atrial flutter (AT) by the atrial rhythm classification (ARC) algorithm had a higher ATP conversion success rate than episodes identified as atrial fibrillation (AF); 66.7% for AT and 26.4% for AF. Patients with only ventricular tachyarrhythmias had 690 documented episodes, 401 terminated spontaneously, 248 (85.8%) were terminated by ATP and 41 by shock.
CONCLUSION: Seventy-seven percent of patients with an ICD indication had spontaneous atrial and/or ventricular tachyharrhythmias within the first 6 months after ICD implantation. ATP therapy terminated 58% of all atrial tachyarrhytmias and 66.7% of the atrial flutters. The dual chamber ICD detected, classified and terminated all ventricular tacharrhythmias appropriately.

Entities:  

Mesh:

Year:  2005        PMID: 15744468     DOI: 10.1007/s10840-005-6551-5

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  14 in total

Review 1.  Clinical experience with implantable atrial and combined atrioventricular defibrillators.

Authors:  W Jung; C Wolpert; B Esmailzadeh; S Spehl; S Herwig; B Schumacher; T Lewalter; H Omran; R Schimpf; C Vahlhaus; A Welz; B Lüderitz
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

Review 2.  Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology.

Authors:  S Lévy; G Breithardt; R W Campbell; A J Camm; J C Daubert; M Allessie; E Aliot; A Capucci; F Cosio; H Crijns; L Jordaens; R N Hauer; F Lombardi; B Lüderitz
Journal:  Eur Heart J       Date:  1998-09       Impact factor: 29.983

3.  Atrial defibrillation with a transvenous lead: a randomized comparison of active can shocking pathways.

Authors:  M Cooklin; M R Olsovsky; R G Brockman; S R Shorofsky; M R Gold
Journal:  J Am Coll Cardiol       Date:  1999-08       Impact factor: 24.094

Review 4.  Current clinical perspectives on implantable devices for atrial defibrillation.

Authors:  Giuseppe Boriani; Mauro Biffi; Cristian Martignani; Richard Luceri; Pietro Bartolini; Angelo Branzi
Journal:  Curr Opin Cardiol       Date:  2002-01       Impact factor: 2.161

5.  Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Oucome dello Scompenso Cardiaco in relazione all'Utilizzo delle Risore.

Authors:  P Bellotti; L P Badano; N Acquarone; R Griffo; G Lo Pinto; A P Maggioni; C Mattiauda; G Menardo; P Mombelloni
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

6.  Safety and efficacy of advanced atrial pacing therapies for atrial tachyarrhythmias in patients with a new implantable dual chamber cardioverter-defibrillator.

Authors:  Anne M Gillis; Christina Unterberg-Buchwald; Herwig Schmidinger; Santini Massimo; Kevin Wolfe; Deborah J Kavaney; Mary F Otterness; Stefan H Hohnloser
Journal:  J Am Coll Cardiol       Date:  2002-11-06       Impact factor: 24.094

7.  Atrial defibrillation thresholds of electrode configurations available to an atrioventricular defibrillator.

Authors:  M E Benser; G P Walcott; C R Killingsworth; S D Girouard; M M Morris; R E Ideker
Journal:  J Cardiovasc Electrophysiol       Date:  2001-08

8.  Efficacy of pacing therapies for treating atrial tachyarrhythmias in patients with ventricular arrhythmias receiving a dual-chamber implantable cardioverter defibrillator.

Authors:  S W Adler; C Wolpert; E N Warman; S K Musley; J L Koehler; D E Euler
Journal:  Circulation       Date:  2001-08-21       Impact factor: 29.690

9.  Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study.

Authors:  G C Grönefeld; O Mauss; Y G Li; T Klingenheben; S H Hohnloser
Journal:  J Cardiovasc Electrophysiol       Date:  2000-11

10.  Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias.

Authors:  M R Gold; N Sulke; D S Schwartzman; R Mehra; D E Euler
Journal:  J Cardiovasc Electrophysiol       Date:  2001-11
View more
  2 in total

1.  Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trial.

Authors:  Giovanni Luca Botto; Giuseppe Boriani; Stefano Favale; Maurizio Landolina; Giulio Molon; Claudio Tondo; Mauro Biffi; Giuseppe Grandinetti; Paolo De Filippo; Giovanni Raciti; Luigi Padeletti
Journal:  Trials       Date:  2011-02-15       Impact factor: 2.279

Review 2.  Inappropriate shocks in patients with ICDs: single chamber versus dual chamber.

Authors:  Juliana Gonçalves; Telmo Pereira
Journal:  Arq Bras Cardiol       Date:  2013-07-02       Impact factor: 2.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.